Catakovic reported that blockage of TIGIT by recombinant TIGIT-Fc would reduce CLL viability in vitro due to decreasing production of pro-survival cytokines IL-10 (45). This evidence concerns the gene TIGIT and B-cell chronic lymphocytic leukemia.